Skip to Content
MilliporeSigma
All Photos(2)

Documents

17-10400

Sigma-Aldrich

Anti-phospho-MLKL (Ser358) Antibody Set

from rabbit, purified by affinity chromatography

Synonym(s):

Mixed lineage kinase domain-like protein, MLKL

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human

technique(s)

western blot: suitable

UniProt accession no.

shipped in

wet ice

target post-translational modification

phosphorylation (pSer358)

Gene Information

human ... MLKL(197259)

General description

Mixed lineage kinase domain-like protein (MLKL) is required for the execution of programmed necrosis. MLKL is a cell-permeable acrylamide compound that inhibits human, but not murine, MLKL adaptor function via covalent modification of Cys86. MLKL prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with further downstream effectors.
This phospho-MLKL (Ser358) antibody set contains one vial of phospho-MLKL (Ser358) antibody and one vial of MLKL “Total” antibody.

RECOMMENDED USAGE:
It is recommended to first perform immunoprecipitation on your sample using the non-phosphorylated MLKL antibody for “total” MLKL protein isolation (see protocol section on page 2 of the Certificate of Analysis); then use the immunoprecipitated sample to detect the phosphorylated protein using the phospho-MLKL (Ser358) antibody via western blot.

Specificity

When used together and under the “Recommended Usage” instructions, this antibody set will detect MLKL phosphorylated at Ser358.

Immunogen

Epitope: Ser358
Linear peptide corresponding to the Protein Kinase Domain of phospho-MLKL (Ser358).

Application

Western Blot Analysis:
Untreated HT-29 cell lysates or lysates from HT-29 cells treated with Cycloheximide,Z-VAD-FMK and TNF alpha were first immunoprecipitated using the Anti-MLKL “total” antibody (1:1000 dilution) to isolate the MLKL protein.
The isolated “total” MLKL protein sample was then probed with Anti-phospho-MLKL (Ser358) (1:1000 dilution).
Anti-phospho-MLKL (Ser358) Antibody Set is an antibody set against phospho-MLKL (Ser358) for use in WB.

Components

One vial of phospho-MLKL (Ser358) antibody

One vial of MLKL “Total” antibody

Quality

Anti- MLKL (Total Antibody): Evaluated by Immunoprecipitation on HT-29 cell lysates.

Anti-phospho-MLKL (Ser358) Antibody: Evaluated by Dot Blot on phosphorylated and non-phosphorylated MLKL peptides.

Target description

~54 kDa

Physical form

100 µL of Anti-phospho-MLKL (Ser358) purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.

100 µg (concentration: 1 mg/mL) of Anti- MLKL purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Not finding the right product?  

Try our Product Selector Tool.

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Abdulrahman Allaf et al.
Cold Spring Harbor molecular case studies, 8(4) (2022-06-23)
Schwannomatosis is a rare genetic disorder that predisposes individuals to development of multiple schwannomas mainly in spinal and peripheral nerves and to debilitating chronic pain often unrelated to any schwannoma. Pathogenic variants of two genes, SMARCB1 and LZTR1, are causal
R S Al-Lamki et al.
Cell death & disease, 7(6), e2287-e2287 (2016-07-01)
We previously reported that renal clear cell carcinoma cells (RCC) express both tumor necrosis factor receptor (TNFR)-1 and -2, but that, in organ culture, a TNF mutein that only engages TNFR1, but not TNFR2, causes extensive cell death. Some RCC
Qiong Wang et al.
Translational oncology, 13(2), 372-382 (2019-12-31)
The efficacy of chemotherapeutic agents in killing cancer cells is mainly attributed to the induction of apoptosis. However, the tremendous efforts on enhancing apoptosis-related mechanisms have only moderately improved lung cancer chemotherapy, suggesting that other cell death mechanisms such as

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service